5.860

-0.090 (-1.51%)
价格区间 5.790 - 5.970   (3.11%)
开盘 5.950
昨收 5.950
2.880
买盘 9
3.300
卖盘 8
成交量 384,240
成交额 -
注释
数据延迟。最后一次更新16 Nov 2024 05:00.
数据提供商
查看所有活动

关于 ABEONA THERAPEUTICS INC

Abeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, the Company is also developing rare plasma protein therapies including SDF Alpha (alpha-1 protease inhibitor) for inherited COPD using its SDF (Salt Diafiltration) ethanol-free process.

There are 3 follower

粉丝
3
粉丝
43
粉丝
0